Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2009-04-27
2011-10-25
Rawlings, Stephen (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S277100, C530S300000, C530S328000, C435S007100, C435S007800, C435S034000, C435S320100, C435S325000, C536S023500
Reexamination Certificate
active
08043623
ABSTRACT:
Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. Several specific, non-limiting examples of these polypeptides are set forth as SEQ ID NOs: 3-7. Nucleic acids encoding these polypeptides, and host cells transfected with these nucleic acids, are also disclosed. Methods of using these polypeptides, and polynucleotides encoding these polypeptides, for the treatment of breast and prostate cancer are also disclosed.
REFERENCES:
patent: 5763219 (1998-06-01), Keyomarsi
patent: 6326471 (2001-12-01), Kokolus et al.
patent: 6387888 (2002-05-01), Mincheff et al.
patent: 6500641 (2002-12-01), Chen et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: WO 99/61068 (1999-12-01), None
patent: WO 01/04309 (2001-01-01), None
patent: WO 02/077012 (2002-10-01), None
patent: WO 03/009814 (2003-02-01), None
Altuvia et al., “A Structure-Based Algorithm to Predict Potential Binding Peptides to MHC Molecules with Hydrophobic Binding Pockets,”Human Immunol. 58:1-11 (1997).
Amalfitano et al., “Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy,”Current Gene Therapy, 2:111-133 (2002).
Andersen et al., “Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules,”Tissue Antigens., 55(6):519-531 (2000).
Arceci, “The potential for antitumor vaccination in acute myelogenous leukemia,”J. Molecular Medicine, 76:80-93 (1998).
Bergers et al., “Extrinsic regulators of epithelial tumor progression: metalloproteinases,”Current Opinion in Genetics and Development, 10:120-127 (2000).
Bins et al., “Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients,”J. Immunother., 30(2):234-239 (2007).
Bocchia et al., “Antitumor vaccination: where we stand,”Haematologica, 85:1172-1206 (2000).
Bodey et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,”Anticancer Research20:2665-2676 (2000).
Boon et al., “Toward a Genetic Analysis of Tumor Rejection Antigens,”Advances in Cancer Research58:177-211 (1999).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1310 (1990).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell Biology111:2129-2138 (1990).
Carlsson et al., “Generation of Cytotoxic T Lymphocytes Specific for the Prostate and Breast Tissue Antigen TARP,”The Prostate61:161-170 (2004).
Cheng et al., “Characterization of the Androgen-Regulated Prostate-Specific T Cell Receptor γ-Chain Alternate Reading Frame Protein (TARP) Promoter,”Endocrinology144(8):3433-3440 (2003).
Corman et al., “Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 cells,”Clin Exp Immunol. 114(2):166-172 (1998) (Abstract Only).
Correale et al., “In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived from Prostate-Specific Antigen,”J. Natl. Cancer Institute89(4):293-300 (1997).
Cox et al., “Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines,”Science, 264:716-719 (1994).
Critchfield et al., “The Future of DNA Diagnostics,”Disease Markers15:108-111 (1999).
Daniel et al., “Mapping of Linear Antigenic Sites on the S Glycoprotein of a Neurotropic Murine Coronavirus with Synthetic Peptides: A Combination of Nine Prediction Algorithms Fails to Identify Relevant Epitopes and Peptide Immunogenicity is Drastically Influenced by the Nature of the Protein Carrier,”Virology, 202:540-549 (1994).
Davodeau et al., “Secretion of Disulfide-linked Human T-cell Receptor γδ Heterodimers,”The Journal of Biological Chemistry, 268(21):15455-15460 (1993).
Denkberg et al., “Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies,”J. Immunol. 169(8):4399-4407 (2002) (Abstract Only).
Essand et al., “High expression of a specific T-cell receptor γ transcript in epithelial cells of the prostate,”Proc. Natl. Acad. Sci. USA, 96:9287-9292 (1999).
Ezzell, “Cancer ‘Vaccines’: An Idea Whose Time Has Come?”J. NIH Research7:46-49 (1995).
Feltkamp et al., “Efficient MHC Class I-Peptide Binding is Required but does not Ensure MHC Class I-Restricted Immunogenicity,”Mol. Immunol., 31(18):1391-1401 (1994).
Fisk et al., “Changes in an HER-2 Peptide Upregulating HLA-A2 Expression Affect Both Conformational Epitopes and CTL Recognition: Implications for Optimization of Antigen Presentation and Tumor-Specific CTL Induction,”J. Immunother. Emphasis Tumor Immunol., 18(4):197-209 (1995).
Gao et al., “Tumor Vaccination That Enhances Antitumor T-Cell Responses Does Not Inhibit the Growth of Established Tumors Even in Combination With Interleukin-12 Treatment: The Importance of Inducing Intratumoral T-Cell Migration,”J. Immunother., 23:643-653 (2000).
Greenspan et al., “Defining epitopes: It's not as easy as it seems,”Nature Biotechnology17:936-937 (1999).
Greten et al., “Peptide-β2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes,”J. Immunol. Methods271(1-2):125-135 (2002) (Abstract Only).
Guichard et al., “Melanoma Peptide MART-1(27-35) Analogues with Enhanced Binding Capacity to the Human Class I Histocompatibility Molecule HLA-A2 by Introduction of a β-Amino Acid Residue: Implications for Recognition by Tumor-Infiltrating Lymphocytes,”J. Med. Chem. 43:3803-3808 (2000).
Gura, “Systems for Identifying New Drugs are Often Faulty,”Science278:1041-1042 (1997).
Hawkins et al., “PEDB: the Prostate Expression Database,”Nucleic Acids Research, 27(1):204-208 (1999).
Heiser et al., “Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplfied Tumor RNA,”J. Immunol. 166:2953-2960 (2001).
Holmes, “Expert Opinion on Investigational Drugs,”Exp. Opin. Invest. Drugs, 10(3):511-519 (2001).
Hu et al., “Enhancement of Cytolytic T Lymphocyte Precursor Frequency in Melanoma Patients following Immunization with the MAGE-1 Peptide Loaded Antigen Presenting Cell-based Vaccine,”Cancer Research, 56:2479-2483 (1996).
Huang et al., “Prostate cancer expression profiling by cDNA sequencing analysis,”Genomics, 59(2):178-186 (1999) (EMEST Database Entry AI557112, Accession No. AI557112).
Huard et al., “The critical role of a solvent-exposed residue of an MHC class I-restricted peptide in MHC-peptide binding,”Int. Immunol., 9(11):1701-1707 (1997).
Jaeger et al., “Generation of Cytotoxic T-Cell Responses with Synthetic Melanoma-Associated Peptides In Vivo: Implications for Tumor Vaccines with Melanoma-Associated Antigens,”International Journal of Cancer, 66:162-169 (1996).
Johansen et al., “Peptide binding to MHC class I is determined by individual pockets in the binding groove,”Scand J. Immunol. 46(2):137-146 (1997) (Abstract Only).
Kelland, “‘Of mice and men’: values and liabilities of the athymic nude mouse model in anticancer drug development,”Eur. J. Cancer., 40(6):827-836
Berzofsky Jay A.
Oh SangKon
Pastan Ira
Klarquist & Sparkman, LLP
Rawlings Stephen
The Government of the United States of America as represented by
LandOfFree
Immunogenic peptides for the treatment of prostate and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic peptides for the treatment of prostate and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides for the treatment of prostate and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271754